This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HCV	Diacylglycerol O-acyltransferase-1 (DGAT1)	<p><i>In vitro</i> studies suggest that inhibiting DGAT1 could help treat HCV infection. In cultured human hepatoma cells or primary human hepatocytes, <i>DGAT1</i> knockdown or a small molecule DGAT1 inhibitor decreased production of infectious viral particles compared with vehicle. Next steps include testing the DGAT1 inhibitor in humanized mice.</p> <p>Roche and Via Pharmaceuticals Inc. have a DGAT1 inhibitor in preclinical testing for metabolic diseases.</p> <p>SciBX 3(41); doi:10.1038/scibx.2010.1234 Published online Oct. 21, 2010</p>	Patent application filed; available for licensing	<p>Herker, E. <i>et al. Nat. Med.</i>; published online Oct. 10, 2010; doi:10.1038/nm.2238</p> <p>Contact: Melanie Ott, The J. David Gladstone Institutes, San Francisco, Calif. e-mail: mott@gladstone.ucsf.edu</p>